Trial Radar
Sign in

Friday, August 21

Intelligence landscape

Structured registry intelligence cross-referenced with ClinicalTrials.gov — signal velocity, sector activity, and entity monitoring. Breast Cancer leads active signals with 2,473 open studies.

Explore entities
502,098
Tracked entities
65,203 (13%)
Active signals
4,136
Phase III active
35,831
New signals (YTD)
96,900
Record updates (YTD)
4,479
Avg signals / mo

Daily Intelligence Brief

Today's lead story

Recurring editorial brief structured from registry signals — the flagship intelligence feed for enterprise subscribers.

ClinicalTrials.gov count · refreshed hourly

Breast Cancer leads recruiting activity on ClinicalTrials.gov

Friday, August 21, 2026 · Template brief

ClinicalTrials.gov currently lists 502,098 registered studies, with 65,203 open to enrollment. 4,136 Phase III trials are actively recruiting — the late-stage pipeline that often signals upcoming readouts and regulatory decisions.

Breast Cancer has 2,473 recruiting studies, making it one of the most active therapeutic areas in the registry today. Use Explore to filter by condition, sponsor, or intervention.

  • 502,098 trials on ClinicalTrials.gov
  • 65,203 recruiting
  • 4,136 Phase III recruiting
  • Breast Cancer: 2,473 recruiting
  • 35,831 new trials posted YTD

Signal velocity

Registration velocity

New signal postings and record updates — primary indicators of sector momentum on ClinicalTrials.gov.

ClinicalTrials.gov count · refreshed hourly

3,066

New registrations (MTD)

13,109

Registry updates (MTD)

4,479

Avg registrations / month (YTD)

2.7×

Update-to-registration ratio (YTD)

Monthly registry activity

New study registrations and record updates on ClinicalTrials.gov
New registrationsRegistry updates

Cumulative YTD registrations

Running registration and update totals for 2026
New registrationsRegistry updates

Pipeline

Pipeline status

9% of Phase III studies are open for enrollment. 0% interventional; 86% of allocatable studies are randomized.

ClinicalTrials.gov count · refreshed hourly

Overall status distribution

Registered studies by overall status on ClinicalTrials.gov

Enrollment by phase

Registered studies vs open enrollment by development phase
Registered studiesOpen enrollment

Study design distribution

Interventional, observational, and expanded access studies

Study design counts load from ClinicalTrials.gov.

Randomization model

Registered studies with randomized vs non-randomized allocation

Therapeutic areas

Indication & intervention coverage

Breast Cancer leads open enrollment with 2,473 recruiting studies. 28% of open-enrollment studies are Phase III–IV.

ClinicalTrials.gov count · refreshed hourly

Trials by indication

Registered studies vs open enrollment by therapeutic area

Trials by intervention

Open enrollment and registered studies by intervention or modality

Entities

Entity portfolio

Pfizer leads with 6,069 tracked entities, 239 active signals.

ClinicalTrials.gov count · refreshed hourly

Sponsor portfolio volume

Registered studies and open enrollment by sponsor
Registered studiesOpen enrollment

Open enrollment rate by sponsor

Share of each sponsor portfolio actively enrolling patients

Top entities

Ranked by tracked entity count

  1. 1

    Pfizer

    239 open enrollment · 4% enrollment rate

    6,069

    entities

  2. 2

    Merck

    347 open enrollment · 7% enrollment rate

    5,206

    entities

  3. 3

    Novartis

    273 open enrollment · 5% enrollment rate

    5,073

    entities

  4. 4

    GSK

    135 open enrollment · 3% enrollment rate

    4,945

    entities

  5. 5

    AstraZeneca

    374 open enrollment · 8% enrollment rate

    4,793

    entities

  6. 6

    Sanofi

    145 open enrollment · 4% enrollment rate

    3,428

    entities

  7. 7

    Roche

    178 open enrollment · 6% enrollment rate

    3,157

    entities

  8. 8

    Johnson & Johnson

    3 open enrollment · 1% enrollment rate

    267

    entities

Market movers

Notable trials

Late-stage and recently updated studies from recent registry activity.

Browse Phase III →